AU2011253602B2 — Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Assigned to Vero Biotech Inc · Expires 2012-08-23 · 14y expired
What this patent protects
CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITRIC OXIDE (NO) Abstract Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide 5 to nitric oxide employs a surface-active …
USPTO Abstract
CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITRIC OXIDE (NO) Abstract Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide 5 to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.
Drugs covered by this patent
- Inomax (NITRIC OXIDE) · Vero Biotech Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.